Next Article in Journal
A Profit Maximization Model for Data Consumers with Data Providers’ Incentives in Personal Data Trading Market
Previous Article in Journal
An Urban Traffic Dataset Composed of Visible Images and Their Semantic Segmentation Generated by the CARLA Simulator
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Data Descriptor

Single-Nucleotide Variants in PADI2 and PADI4 and Ancestry Informative Markers in Interstitial Lung Disease and Rheumatoid Arthritis among a Mexican Mestizo Population

by
Karol J. Nava-Quiroz
1,2,
Jorge Rojas-Serrano
3,
Gloria Pérez-Rubio
1,
Ivette Buendia-Roldan
4,
Mayra Mejía
5,
Juan Carlos Fernández-López
6,
Espiridión Ramos-Martínez
7,
Luis A. López-Flores
1,
Alma D. Del Ángel-Pablo
1 and
Ramcés Falfán-Valencia
1,*
1
HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Tlalpan, Mexico City 14080, Mexico
2
Programa de Doctorado en Ciencias Médicas, Odontológicas y de la Salud, Investigación Clínica Experimental en Salud, Bioquímica Clínica, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico
3
Rheumatology Clinic, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Tlalpan, Mexico City 14080, Mexico
4
Translational Research Laboratory on Aging and Pulmonary Fibrosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Tlalpan, Mexico City 14080, Mexico
5
Diffuse Interstitial Lung Disease Clinic, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Tlalpan, Mexico City 14080, Mexico
6
Consorcio de Genómica Computacional, Instituto Nacional de Medicina Genómica (INMEGEN), Tlalpan, Mexico City 14610, Mexico
7
Experimental Medicine Research Unit, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 06720, Mexico
*
Author to whom correspondence should be addressed.
Submission received: 22 September 2023 / Revised: 6 December 2023 / Accepted: 18 December 2023 / Published: 25 December 2023

Abstract

:
Rheumatoid arthritis (RA) is an autoimmune disease mainly characterized by joint inflammation. It presents extra-articular manifestations, with the lungs being one of the affected areas. Among these, damage to the pulmonary interstitium (Interstitial Lung Disease—ILD) has been linked to proteins involved in the inflammatory process and related to extracellular matrix deposition and lung fibrosis establishment. Peptidyl arginine deiminase enzymes (PAD), which carry out protein citrullination, play a role in this context. A genetic association analysis was conducted on genes encoding two PAD isoforms: PAD2 and PAD4. This analysis also included ancestry informative markers and protein level determination in samples from patients with RA, RA-associated ILD, and clinically healthy controls. Significant single nucleotide variants (SNV) and one haplotype were identified as susceptibility factors for RA-ILD development. Elevated levels of PAD4 were found in RA-ILD cases, while PADI2 showed an association with RA susceptibility. This work presents data obtained from previously published research. Population variability has been noticed in genetic association studies. We present data for 14 SNVs that show geographical and genetic variation across the Mexican population, which provides highly informative content and greater intrapopulation genetic diversity. Further investigations in the field should be considered in addition to AIMs. The data presented in this study were analyzed in association with SNV genotypes in PADI2 and PADI4 to assess susceptibility to ILD in RA, as well as with changes in PAD2 and PAD4 protein levels according to carrier genotype, in addition to the use of covariates such as ancestry markers.
Dataset: DOI 10.3390/cells12182235 (published manuscript.). The datasets generated for this study can be found in ClinVar accessions SCV001422427–SCV001422434.
Dataset License: Attribution 4.0 International (CC BY 4.0)

1. Summary

This work presents data obtained from previously published research [1]. Rheumatoid arthritis (RA) is an autoimmune disease that is primarily inflammatory, affecting the joints [2,3]. Extra-articular manifestations of the disease have been described, including damage to the lung interstitium (interstitial lung disease, ILD) [4].
Regarding factors associated with developing both diseases (RA and RA-ILD), smoking has been described as one of the main risk factors, in addition to genetic predisposition and occupational and environmental factors [5,6]. These exposures and predisposing factors alter the pulmonary environment, initially causing inflammation in both the lung and the joint [7].
In the inflammatory process, several interleukins, such as IL-6 [8], IL-1β [9], and TNF-α [10], have been proposed as possible biomarkers. One of the markers used with high sensitivity and specificity for RA is anti-citrullinated peptide antibodies (ACPA). However, in the presence of ILD, there is usually no change in positivity or levels to indicate a worse prognosis [11]. ACPA are antibodies that recognize citrullinated proteins; this process is carried out by peptidyl arginine deiminases (PAD) [12,13].
It has been linked to the involvement of proteins participating in the inflammatory process and associated with extracellular matrix deposition and fibrosis establishment in the lungs, such as PAD enzymes [14]. The most abundant isoforms in the lung are PAD2 and PAD4 [15,16].
Multiple SNVs in genes encoding PAD enzymes have been described in different populations, such as rs1748033 in PADI4, which has been associated with susceptibility to RA in Japanese [17,18], Korean [19], Indian [20,21], Iranian [22], and Netherlands [23] populations, as well as altered PAD4 protein levels, which correlate with the presence of anti-citrullinated peptide antibodies and levels of inflammatory proteins such as rheumatoid factor and C-reactive protein [11,24].
The prevalence of musculoskeletal ”Ise’ses in Mexico has been reported to vary by geographic location [25], leading to an analysis of private markers within the Mexican population obtained by Silva et al. in 2009 [26]. Therefore, exposure to biomass burning smoke, smoking, PAD2 and PAD4 protein levels, SNVs in the genes encoding these enzymes, and ancestry markers were assessed in the Mexican population in groups of patients with interstitial lung disease, rheumatoid arthritis, and individuals without the disease.

2. Data Description

The data obtained in each analysis are presented and described in the tables and figures.

2.1. Study Groups

The included groups consisted of patients with rheumatoid arthritis (RA group), RA associated with interstitial lung disease (RA-ILD group), as well as a group of clinically healthy subjects (CHS group). These groups are displayed in the result tables.

2.2. Genotyping

Table 1 displays the analysis variable at the top of each column, including the gene, the SNV with their respective genotypes or alleles, and the patient or control group. The rows represent the frequency in percentage.
In Figure 1, diamond plots depict haplotype blocks identified in PADI2 and PADI4 within the Mexican mestizo population. The diamonds, connected by lines to form a block, represent a haplotype. At the top of the graph, you can see the seven SNVs, with each diamond symbolizing the linkage between these loci. Diamonds with a deeper shade of red indicate a higher degree of linkage disequilibrium, while lighter diamonds suggest a lower degree of linkage disequilibrium. The diamonds also display the linkage disequilibrium as ‘r’ (Pearson’s Correlation Coefficient).
The haplotype analysis was conducted between all groups of patients with RA (with and without ILD) and the group of individuals without the diseases (Figure 1a), as well as within RA-ILD patients vs. RA patients (Figure 1b).
Table 2 displays the percentage frequencies of the haplotypes identified in PADI4 (rs11203366-rs11203367-rs1748033-rs874881) within the patient populations of RA-ILD, RA and the group of individuals without the diseases (clinically healthy subjects-CHS), as shown in Figure 1a,b.

2.3. AIMs

The genotyping of ancestry informative markers consists of 14 private SNVs between chromosomes 1 and 13. These markers exhibit differential minor allele frequencies (MAF) between the ZAP and CEU populations (taken as reference). Table 3 presents the results of the minor allele frequency in the reference populations, and at the end of the table, you can find the MAF for the study population (n = 867 individuals).
The assessment of genetic distances between the study groups was carried out using the 14 SNVs presented in Table 3. To do this, we conducted a group comparison analysis, and the results of the FST index, along with their corresponding p-values, are shown in Table 4 for the comparisons between the respective row and column.

2.4. Eigenvectors PCA

Figure 2 displays a Principal Component Analysis (PCA) where the CEU and ZAP populations are taken as reference groups. In this analysis, the control group consists of clinically healthy individuals from the CHS group, and the case group includes all patients from the RA and RA-ILD groups. The first two vectors are shown, collectively providing more than 85% of the information within the population.

2.5. Exposures and Protein PAD2 and PAD4 Levels

In Figure 3a, the serum levels of PAD4 protein are displayed, and in Figure 3b, the PAD2 protein levels are shown for the three study groups. Each symbol (circle, triangle, and black square) represents an individual in whom the protein was measured.
Figure 4 displays the levels of PAD4 and PAD2 proteins according to exposure to smoking (a and c) or biomass (b and d), which are the primary environmental factors associated with the risk of both lung and joint diseases. In each figure, median values and interquartile ranges are depicted using box-and-whisker plots. The classification is based on smoking status or, in the case of exposure to biomass-burning smoke.

2.6. Proteins in BAL Samples

Figure 5 presents the levels of PAD2 and PAD4 proteins, specifically measured in patients diagnosed with RA-ILD who underwent bronchoscopy for diagnostic purposes. Each square in the figure represents one sample from a patient.

3. Methods

The genetic data analysis was conducted using Plink v1.07 [27]. A total of 23 SNVs were assessed in 907 individuals, with the analysis divided into two parts: initially, 14 AIMs were examined independently, followed by an investigation of 8 SNVs, including four from PADI2 and four from PADI4, for genetic association analysis.
A quality control process was implemented for all polymorphisms to ensure data quality. Individuals with more than 5% missing data, attributed to unsuccessful genotyping of SNVs, were excluded, resulting in the removal of 40 individuals. Additionally, a marker-level evaluation of the Hardy–Weinberg equilibrium was performed, leading to the exclusion of SNV rs2235926 in PADI2 (p = 8.9 × 10−24).
Ancestry markers were analyzed in Plink v1.07, utilizing CEU and ZAP as reference populations, obtained from Phase 3 of the 1000 Genomes Project and the International HapMap Project (websites: http://browser.1000genomes.org and https://ftp.ncbi.nlm.nih.gov/hapmap, respectively; accessed 1 July 2021) [26,28]. The FST index was assessed in R using the “Fine Pop” package, and distances among the three study groups were analyzed within a matrix, calculating the global FST [29].
Protein levels were analyzed through non-parametric tests comparing the three groups. Medians and interquartile ranges were assessed using the Kruskal–Wallis test, and these statistics are presented in box-and-whisker plots for protein levels.
The graphs and statistical analyses of the protein and quantitative variables were carried out in the R environment (v.4.3.1), using the packages “ggplot2”, “dplyr”, “tidyverse”, “ggpubr” and “stats” [29].

Ethical Statement

Approval for this study was obtained from the Research Institutional Committees for Research, Biosecurity, and Research Ethics at the Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER) under the approval codes B20-15 and C08-15. All participants were granted their authorization and signed informed consent forms. INER provided a document ensuring the safeguarding, including the adequate handling of personal data as sensitive and confidential information. The research adhered to the guidelines outlined in the 1975 Declaration of Helsinki.

Author Contributions

Conceptualization, K.J.N.-Q., J.R.-S., G.P.-R., I.B.-R. and R.F.-V.; Data curation, K.J.N.-Q., I.B.-R., M.M., J.C.F.-L. and E.R.-M.; Formal analysis, K.J.N.-Q., G.P.-R., M.M., J.C.F.-L., E.R.-M. and A.D.D.Á.-P.; Funding acquisition, R.F.-V.; Investigation, K.J.N.-Q., J.R.-S., G.P.-R., I.B.-R., M.M., J.C.F.-L., E.R.-M., A.D.D.Á.-P. and R.F.-V.; Methodology, K.J.N.-Q., G.P.-R., I.B.-R., J.C.F.-L., L.A.L.-F., A.D.D.Á.-P. and R.F.-V.; Project administration, R.F.-V.; Resources, J.R.-S., M.M., E.R.-M., L.A.L.-F. and R.F.-V.; Software, K.J.N.-Q., G.P.-R., J.C.F.-L., L.A.L.-F. and A.D.D.Á.-P.; Supervision, J.R.-S., M.M. and R.F.-V.; Validation, J.R.-S., G.P.-R., M.M., J.C.F.-L. and A.D.D.Á.-P.; Visualization, J.R.-S. and R.F.-V.; Writing—original draft, K.J.N.-Q., J.R.-S., G.P.-R., E.R.-M. and R.F.-V.; Writing—review and editing, K.J.N.-Q., G.P.-R. and R.F.-V. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The research adhered to the principles of the Declaration of Helsinki and received approval from the Ethics Committee of the Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas” (with protocol codes B20-15 and C08-15).

Informed Consent Statement

Consent was secured from all research participants, encompassing written consent and assurance of personal data confidentiality for publication purposes, both from the patients and healthy subjects who partook in the study.

Data Availability Statement

The datasets generated for this study can be found in ClinVar accessions SCV001422427–SCV001422434.

Acknowledgments

Programa de Maestría y Doctorado en Ciencias Médicas Odontológicas y de la Salud of the Universidad Nacional Autónoma de México (UNAM). Furthermore, the support provided by the Consejo Nacional de Humanidades, Ciencia y Tecnología (National Council of Science and Technology) (CONAHCyT), CVU: 690362.

Conflicts of Interest

All authors declare no conflicts of interest.

References

  1. Nava-Quiroz, K.J.; Rojas-Serrano, J.; Perez-Rubio, G.; Buendia-Roldan, I.; Mejía, M.; Fernández-López, J.C.; Rodríguez-Henriquez, P.; Ayala-Alcantar, N.; Ramos-Martínez, E.; López-Flores, L.A.; et al. Molecular Factors in PAD2 (PADI2) and PAD4 (PADI4) Are Associated with Interstitial Lung Disease Susceptibility in Rheumatoid Arthritis Patients. Cells 2023, 12, 2235. [Google Scholar] [CrossRef] [PubMed]
  2. Kelly, C.; Iqbal, K.; Iman-gutierrez, L.; Evans, P.; Manchegowda, K. Lung Involvement in Inflammatory Rheumatic Diseases. Best Pract. Res. Clin. Rheumatol. 2016, 30, 870–888. [Google Scholar] [CrossRef] [PubMed]
  3. Smolen, J.S.; Landewé, R.; Breedveld, F.C.; Buch, M.; Burmester, G.; Dougados, M.; Emery, P.; Gaujoux-Viala, C.; Gossec, L.; Nam, J.; et al. EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2013 Update. Ann. Rheum. Dis. 2014, 73, 492–509. [Google Scholar] [CrossRef] [PubMed]
  4. Bilgici, A.; Ulusoy, H.; Kuru, O.; Celenk, C.; Ünsal, M.; Danacı, M. Pulmonary Involvement in Rheumatoid Arthritis. Rheumatol. Int. 2005, 25, 429–435. [Google Scholar] [CrossRef]
  5. Regalado, J.; Pérez-Padilla, R.; Sansores, R.; Páramo-Ramirez, J.I.; Brauer, M.; Paré, P.; Vedal, S. The Effect of Biomass Burning on Respiratory Symptoms and Lung Function in Rural Mexican Women. Am. J. Respir. Crit. Care Med. 2006, 174, 901–905. [Google Scholar] [CrossRef] [PubMed]
  6. Devine, M.S.; Garcia, C.K. Genetic Interstitial Lung Disease. Clin. Chest Med. 2012, 33, 95–110. [Google Scholar] [CrossRef]
  7. Ytterberg, A.J.; Joshua, V.; Reynisdottir, G.; Tarasova, N.K.; Rutishauser, D.; Ossipova, E.; Haj Hensvold, A.; Eklund, A.; Sköld, C.M.; Grunewald, J.; et al. Shared Immunological Targets in the Lungs and Joints of Patients with Rheumatoid Arthritis: Identification and Validation. Ann. Rheum. Dis. 2015, 74, 1772–1777. [Google Scholar] [CrossRef]
  8. Favalli, E.G. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatol. Ther. 2020, 7, 473–516. [Google Scholar] [CrossRef]
  9. Barlo, N.P.; Van Moorsel, C.H.M.; Korthagen, N.M.; Heron, M.; Rijkers, G.T.; Ruven, H.J.T.; Van Den Bosch, J.M.M.; Grutters, J.C. Genetic Variability in the IL1RN Gene and the Balance between Interleukin (IL)-1 Receptor Agonist and IL-1β in Idiopathic Pulmonary Fibrosis. Clin. Exp. Immunol. 2011, 166, 346–351. [Google Scholar] [CrossRef]
  10. Vasakova, M.; Sterclova, M.; Kolesar, L.; Slavcev, A.; Pohunek, P.; Sulc, J.; Striz, I. Cytokine Gene Polymorphisms and BALF Cytokine Levels in Interstitial Lung Diseases. Respir. Med. 2009, 103, 773–779. [Google Scholar] [CrossRef]
  11. Palterer, B.; Vitiello, G.; Del Carria, M.; D’Onofrio, B.; Martinez-Prat, L.; Mahler, M.; Cammelli, D.; Parronchi, P. Anti-Protein Arginine Deiminase Antibodies Are Distinctly Associated with Joint and Lung Involvement in Rheumatoid Arthritis. Rheumatology 2023, 62, 2410–2417. [Google Scholar] [CrossRef] [PubMed]
  12. Guderud, K.; Mæhlen, M.T.; Nordang, G.B.; Viken, M.K.; Andreassen, B.K.; Molberg, O.; Flåm, S.T.; Lie, B.A.; Jebsen, K.G. Lack of Association among Peptidyl Arginine Deiminase Type 4 Autoantibodies, PADI4 Polymorphisms, and Clinical Characteristics in Rheumatoid Arthritis. J. Rheumatol. 2018, 45, 1211–1219. [Google Scholar] [CrossRef] [PubMed]
  13. Martinez-Prat, L.; Martinez-Taboada, V.; Santos, C.; Lopez-Hoyos, M.; Mahler, M. Anti-Protein-Arginine Deiminase 4 IgG and IgA Delineate Severe Rheumatoid Arthritis. Diagnostics 2022, 12, 2187. [Google Scholar] [CrossRef] [PubMed]
  14. Sakkas, L.I.; Daoussis, D.; Liossis, S.-N.; Bogdanos, D.P. The Infectious Basis of ACPA-Positive Rheumatoid Arthritis. Front. Microbiol. 2017, 8, 1853. [Google Scholar] [CrossRef]
  15. Makrygiannakis, D.; Hermansson, M.; Ulfgren, A.-K.; Nicholas, A.P.; Zendman, A.J.W.; Eklund, A.; Grunewald, J.; Skold, C.M.; Klareskog, L.; Catrina, A.I. Smoking Increases Peptidylarginine Deiminase 2 Enzyme Expression in Human Lungs and Increases Citrullination in BAL Cells. Ann. Rheum. Dis. 2008, 67, 1488–1492. [Google Scholar] [CrossRef] [PubMed]
  16. Samara, K.D.; Trachalaki, A.; Tsitoura, E.; Koutsopoulos, A.V.; Lagoudaki, E.D.; Lasithiotaki, I.; Margaritopoulos, G.; Pantelidis, P.; Bibaki, E.; Siafakas, N.M.; et al. Upregulation of Citrullination Pathway: From Autoimmune to Idiopathic Lung Fibrosis. Respir. Res. 2017, 18, 218. [Google Scholar] [CrossRef] [PubMed]
  17. Suzuki, A.; Yamada, R.; Chang, X.; Tokuhiro, S.; Sawada, T.; Suzuki, M.; Nagasaki, M.; Nakayama-Hamada, M.; Kawaida, R.; Ono, M.; et al. Functional Haplotypes of PADI4, Encoding Citrullinating Enzyme Peptidylarginine Deiminase 4, Are Associated with Rheumatoid Arthritis. Nat. Genet. 2003, 34, 395–402. [Google Scholar] [CrossRef] [PubMed]
  18. Ikari, K.; Kuwahara, M.; Nakamura, T.; Momohara, S.; Hara, M.; Yamanaka, H.; Tomatsu, T.; Kamatani, N. Association between PADI4 and Rheumatoid Arthritis: A Replication Study. Arthritis Rheum. 2005, 52, 3054–3057. [Google Scholar] [CrossRef]
  19. Kang, C.P.; Lee, H.S.; Ju, H.; Cho, H.; Kang, C.; Bae, S.C. A Functional Haplotype of the PADI4 Gene Associated with Increased Rheumatoid Arthritis Susceptibility in Koreans. Arthritis Rheum. 2006, 54, 90–96. [Google Scholar] [CrossRef]
  20. Panati, K.; Pal, S.; Rao, K.V.; Reddy, V.D. Association of Single Nucleotide Polymorphisms (SNPs) of PADI4 Gene with Rheumatoid Arthritis (RA) in Indian Population. Genes Genet. Syst. 2012, 87, 191–196. [Google Scholar] [CrossRef]
  21. Bagheri-Hosseinabadi, Z.; Mirzaei, M.R.; Esmaeili, O.; Asadi, F.; Ahmadinia, H.; Shamsoddini, B.; Abbasifard, M. Implications of Peptidyl Arginine Deiminase 4 Gene Transcription and Polymorphisms in Susceptibility to Rheumatoid Arthritis in an Iranian Population. BMC Med. Genomics 2023, 16, 104. [Google Scholar] [CrossRef] [PubMed]
  22. Hashemi, M.; Zakeri, Z.; Taheri, H.; Bahari, G.; Taheri, M. Association between Peptidylarginine Deiminase Type 4 Rs1748033 Polymorphism and Susceptibility to Rheumatoid Arthritis in Zahedan, Southeast Iran. Iran. J. Allergy. Asthma. Immunol. 2015, 14, 255–260. [Google Scholar] [PubMed]
  23. Kochi, Y.; Thabet, M.M.; Suzuki, A.; Okada, Y.; Daha, N.A.; Toes, R.E.M.; Huizinga, T.W.J.; Myouzen, K.; Kubo, M.; Yamada, R.; et al. PADI4 Polymorphism Predisposes Male Smokers to Rheumatoid Arthritis. Ann. Rheum. Dis. 2011, 70, 512–515. [Google Scholar] [CrossRef] [PubMed]
  24. Jonsson, M.K.; Kantyka, T.; Falkowski, K.; Aliko, A.; Aga, A.B.; Lillegraven, S.; Sexton, J.; Fevang, B.T.; Mydel, P.; Haavardsholm, E.A. Peptidylarginine Deiminase 4 (PAD4) Activity in Early Rheumatoid Arthritis. Scand. J. Rheumatol. 2020, 49, 87–95. [Google Scholar] [CrossRef] [PubMed]
  25. Peláez-Ballestas, I.; Sanin, L.H.; Moreno-Montoya, J.; Alvarez-Nemegyei, J.; Burgos-Vargas, R.; Garza-Elizondo, M.; Rodríguez-Amado, J.; Goycochea-Robles, M.V.; Madariaga, M.; Zamudio, J.; et al. Epidemiology of the Rheumatic Diseases in Mexico. A Study of 5 Regions Based on the COPCORD Methodology. J. Rheumatol. 2011, 38, 3–6. [Google Scholar] [CrossRef]
  26. Silva-Zolezzi, I.; Hidalgo-Miranda, A.; Estrada-Gil, J.; Fernandez-Lopez, J.C.; Uribe-Figueroa, L.; Contreras, A.; Balam-Ortiz, E.; Bosque-Plata, L.; Velazquez-Fernandez, D.; Lara, C.; et al. Analysis of Genomic Diversity in Mexican Mestizo Populations to Develop Genomic Medicine in Mexico. Proc. Natl. Acad. Sci. USA 2009, 106, 8611–8616. [Google Scholar] [CrossRef]
  27. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.; Bender, D.; Maller, J.; Sklar, P.; de Bakker, P.; Daly, M.J.; et al. PLINK: A Toolset for Whole-Genome Association and Population-Based Linkage Analysis. Am. J. Hum. Genet. 2007, 81, 559–575. [Google Scholar] [CrossRef]
  28. Pardo-Seco, J.; Martinón-Torres, F.; Salas, A. Evaluating the Accuracy of AIM Panels at Quantifying Genome Ancestry. BMC Genomics 2014, 15, 543. [Google Scholar] [CrossRef]
  29. R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2023. [Google Scholar]
Figure 1. Haplotypes in PADI2 and PADI4. (a) All Rheumatoid Arthritis patients vs. CHS; (b) RA-ILD vs. RA patients. The intensity of the red depends on the linkage disequilibrium; the more intense the red, the greater the binding disequilibrium.
Figure 1. Haplotypes in PADI2 and PADI4. (a) All Rheumatoid Arthritis patients vs. CHS; (b) RA-ILD vs. RA patients. The intensity of the red depends on the linkage disequilibrium; the more intense the red, the greater the binding disequilibrium.
Data 09 00005 g001
Figure 2. Principal component analysis, populations included in this study; the case group comprises patients with RA-ILD and with only RA (orange square), the control group (blue asterisk), and the reference populations CEU (plus purple symbol) and ZAP (green cross).
Figure 2. Principal component analysis, populations included in this study; the case group comprises patients with RA-ILD and with only RA (orange square), the control group (blue asterisk), and the reference populations CEU (plus purple symbol) and ZAP (green cross).
Data 09 00005 g002
Figure 3. Protein levels determined in serum within the three study groups: (a) PAD4 protein levels, (b) PAD2 protein levels. Each circle, triangle, or square represents an individual. CHS: clinically healthy individuals, RA: rheumatoid arthritis, RA-ILD: rheumatoid arthritis associated with interstitial lung disease. ****: Kruskal-Wallis, p = 3.7 × 10−6; ns: Kruskal-Wallis, p = 0.18.
Figure 3. Protein levels determined in serum within the three study groups: (a) PAD4 protein levels, (b) PAD2 protein levels. Each circle, triangle, or square represents an individual. CHS: clinically healthy individuals, RA: rheumatoid arthritis, RA-ILD: rheumatoid arthritis associated with interstitial lung disease. ****: Kruskal-Wallis, p = 3.7 × 10−6; ns: Kruskal-Wallis, p = 0.18.
Data 09 00005 g003
Figure 4. Protein levels determined in serum within the three study groups, classified by exposure to smoking or biomass: (a) PAD4 protein levels in individuals exposed to smoking. (b) PAD4 protein levels in individuals exposed to biomass-burning smoke. (c) PAD2 protein levels in individuals classified by smoking status. (d) PAD2 levels based on biomass status. ND—Data not available. The dots outside the boxes and whiskers represent outliers.
Figure 4. Protein levels determined in serum within the three study groups, classified by exposure to smoking or biomass: (a) PAD4 protein levels in individuals exposed to smoking. (b) PAD4 protein levels in individuals exposed to biomass-burning smoke. (c) PAD2 protein levels in individuals classified by smoking status. (d) PAD2 levels based on biomass status. ND—Data not available. The dots outside the boxes and whiskers represent outliers.
Data 09 00005 g004
Figure 5. PAD2 and PAD4 protein levels determined in bronchioalveolar lavage (BAL) from 22 patients in the RA-ILD group.
Figure 5. PAD2 and PAD4 protein levels determined in bronchioalveolar lavage (BAL) from 22 patients in the RA-ILD group.
Data 09 00005 g005
Table 1. Analysis of genotypes and alleles of SNV in PADI2 and PADI4.
Table 1. Analysis of genotypes and alleles of SNV in PADI2 and PADI4.
RA-ILD (n = 118)RA (n = 133)CHS (n = 616)
GeneGenotype or AlleleF%F%F%
PADI2rs2057094
GG35.5940.5443.67
GA23.7322.5230.19
AA40.6836.9426.14
G47.4651.858.77
A52.5448.241.23
rs2076615
AA46.0942.7330.86
AC50.4353.6463.86
CC03.4803.6405.28
A71.3069.5562.79
C28.7030.4537.21
rs1005753
TT48.7263.0646.72
TG44.4435.1444.10
GG06.8401.8009.18
T70.9480.6368.77
G29.0619.3731.23
PADI4rs11203366
GG21.5535.9630.50
GA52.5950.0047.00
AA25.8614.0420.90
G47.8460.9654.85
A52.1639.0445.14
rs11203367
TT22.5236.5229.70
TC59.4651.3048.30
CC18.0212.1720.60
T52.2562.1754.60
C47.7537.8345.40
rs1748033
CC16.3814.9125.10
CT50.0051.5749.80
TT33.6233.3323.80
C41.3840.7950.66
T58.6259.2149.34
rs874881
CC23.2844.6224.70
CG59.4842.3151.50
GG17.2413.0822.90
C53.0365.7750.90
G46.9534.2349.10
F%: Frequency in Percentage; RA-ILD: rheumatoid arthritis associated to interstitial lung disease group; RA: rheumatoid arthritis group; CHS: clinically healthy subjects.
Table 2. Analysis of genotypes and alleles of SNV in PADI4.
Table 2. Analysis of genotypes and alleles of SNV in PADI4.
PADI4RA-ILD
(n = 118, HF%)
RA
(n = 133, HF%)
CHS
(n = 616, HF%)
HaplotypeHF (%)HF (%)HF (%)
GTTC39.8047.4035.10
ACCG37.7032.2030.80
GTCG5.009.9013.10
ACTC7.202.9010.60
GTCC2.401.404.00
ATTC2.302.501.10
GCCG2.002.401.20
HF% = haplotype frequency in percentage.
Table 3. AIMs polymorphisms used for the calculation of Eigenvectors.
Table 3. AIMs polymorphisms used for the calculation of Eigenvectors.
ChrSNVZAP
(n = 60)
CEU
(n = 120)
DStudy Group
(n = 867)
No.rsA1A2MAFA1A2MAFΔA1A2MAF
1rs4528122TC0.067CT0.1420.792TC0.338
1rs986690GA0.017AG0.250.733GA0.347
4rs10516422GA0.283GA0.0170.267GA0.234
5rs10515716TC0.267CT0.2080.525TC0.432
6rs1878071AC0.317CA0.2170.467AC0.49
9rs4084051TC0.25CT0.1750.575TC0.483
9rs7853112CA0.25AC0.350.4CA0.395
9rs10511491CT0.25TC0.3910.358CT0.358
9rs1039336AG0.133GA0.2420.625GA0.433
9rs10116714AG0.183GA0.050.767AG0.449
9rs1980888GA0.033AG0.10.866GA0.411
9rs4743556CT0.172TC0.1670.661TC0.486
12rs6487927CT0.033CT0.4750.442CT0.275
13rs21471550T0GT0.50.5GT0.15
ZAP: Zapotecs, CEU: Utah Residents with Northern and Western European Ancestry, MAF: Minor Allele Frequency, A: allele1 and 2. D: delta value obtained between MAF in CEU and MAF in ZAP populations.
Table 4. Estimated pairwise comparison of FST index in study groups.
Table 4. Estimated pairwise comparison of FST index in study groups.
Study GroupRA-ILDRA
RA0.32 (0.578)-
CHS0.34 (0.853)0.24 (0.043)
RA: Rheumatoid Arthritis; RA-ILD: RA associated with Interstitial lung disease; CHS: clinically healthy subjects. The FST index (p-value) is shown.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Nava-Quiroz, K.J.; Rojas-Serrano, J.; Pérez-Rubio, G.; Buendia-Roldan, I.; Mejía, M.; Fernández-López, J.C.; Ramos-Martínez, E.; López-Flores, L.A.; Del Ángel-Pablo, A.D.; Falfán-Valencia, R. Single-Nucleotide Variants in PADI2 and PADI4 and Ancestry Informative Markers in Interstitial Lung Disease and Rheumatoid Arthritis among a Mexican Mestizo Population. Data 2024, 9, 5. https://doi.org/10.3390/data9010005

AMA Style

Nava-Quiroz KJ, Rojas-Serrano J, Pérez-Rubio G, Buendia-Roldan I, Mejía M, Fernández-López JC, Ramos-Martínez E, López-Flores LA, Del Ángel-Pablo AD, Falfán-Valencia R. Single-Nucleotide Variants in PADI2 and PADI4 and Ancestry Informative Markers in Interstitial Lung Disease and Rheumatoid Arthritis among a Mexican Mestizo Population. Data. 2024; 9(1):5. https://doi.org/10.3390/data9010005

Chicago/Turabian Style

Nava-Quiroz, Karol J., Jorge Rojas-Serrano, Gloria Pérez-Rubio, Ivette Buendia-Roldan, Mayra Mejía, Juan Carlos Fernández-López, Espiridión Ramos-Martínez, Luis A. López-Flores, Alma D. Del Ángel-Pablo, and Ramcés Falfán-Valencia. 2024. "Single-Nucleotide Variants in PADI2 and PADI4 and Ancestry Informative Markers in Interstitial Lung Disease and Rheumatoid Arthritis among a Mexican Mestizo Population" Data 9, no. 1: 5. https://doi.org/10.3390/data9010005

Article Metrics

Back to TopTop